We recognize the pivotal role of partnerships in driving pioneering science forward. Aligned with our partners’ commitment, we are dedicated to accelerating transformative and life-changing therapies for patients. Leveraging our global DIS® capabilities across discovery and development, we collaborate closely to deliver innovative therapies that redefine treatment paradigms.
Areas of Interest
We are open to various partnership models to maximize the potential of our antibody immunotherapies and to harness the power of our proprietary Drug Intelligence Science (DIS®).
Pipeline
Robust product portfolio focused on immunoscience to treat cancer and inflammation/immunological diseases
- Out-license of select pipeline assets from discovery to clinical programs
- Collaborations to explore novel combinations
- Collaborations and co-development to identify and develop novel therapeutic antibodies
DIS® Platform Engine
Proprietary Drug Intelligence Science (DIS®) provides a uniquely flexible AI/ML-driven single cell solution for target, antibody, and biomarker discovery
- Discovery and validation of novel disease-associated targets from patients
- Biomarker discovery at preclinical and clinical stage for indication selection and patient stratification
- Translational analysis of HiFiBiO Therapeutics’ single-cell database
